Trial · NCT01315795
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
NCT01315795, Phase 2, Phase 3, Completed, Universitaire Ziekenhuizen KU Leuven
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease. Trials, record NCT01315795. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01315795
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
- NCT number
- NCT01315795
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 59 participants, actual
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Conditions
- Polycystic Liver Disease
- Interventions
- Lanreotide Autogel 90 mg and 120 mg
- First posted
- 2011-03-15
- Last updated
- 2014-07-08
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction of total liver volume after 6 months of treatment measured by means of CT-scan. | 6 months | Reduction of total liver volume after 6 months measured by means of CT-scan. |
| Primary | Reduction of total liver volume after 12 months of treatment by means of CT-scan | 12 months | Reduction of total liver volume after 12 months of treatment by means of CT-scan |
| Primary | Reduction of total liver volume after 18 months of treatment by means of CT-scan | 18 months | Reduction of total liver volume after 18 months of treatment by means of CT-scan |
| Secondary | Measurement of total liver and kidney volumes and cyst volumes at baseline. | Baseline | Reduction of total liver volume Reduction of liver cyst volume Additonal reduction of total liver volume in the non responder group. Additonal reduction of liver cyst volume in the non responder group. % of patients with liver reduction \> 100 ml in the non responder group. Reduction of total kidney volume (ADPKD patients only) after 6 months, 1 year and 18 months |
| Secondary | Measurement of total liver and kidney volumes and cyst volumes after 6 months of treatment by means of CT scan | 6 months | Reduction of total liver volume Reduction of liver cyst volume Additonal reduction of total liver volume in the non responder group. Additonal reduction of liver cyst volume in the non responder group. % of patients with liver reduction \> 100 ml in the non responder group. Reduction of total kidney volume (ADPKD patients only) after 6 months, 1 year and 18 months |
| Secondary | Measurement of total liver and kidney volume and cyst volume after 12 months of treatment by means of CT scan. | 12 months | Reduction of total liver volume Reduction of liver cyst volume Additonal reduction of total liver volume in the non responder group. Additonal reduction of liver cyst volume in the non responder group. % of patients with liver reduction \> 100 ml in the non responder group. Reduction of total kidney volume (ADPKD patients only) after 6 months, 1 year and 18 months |
| Secondary | Measurement of total liver and kidney volumes and cyst volumes after 18 months of treatment by means of CT scan | 18 months | Reduction of total liver volume Reduction of liver cyst volume Additonal reduction of total liver volume in the non responder group. Additonal reduction of liver cyst volume in the non responder group. % of patients with liver reduction \> 100 ml in the non responder group. Reduction of total kidney volume (ADPKD patients only) after 6 months, 1 year and 18 months |
| Secondary | Assessment of quality of life at baseline | baseline | Assessment of quality of life at baseline |
| Secondary | Assessment of quality of life after 6 months of treatment | 6 months | Assessment of quality of life after 6 months of treatment |
| Secondary | Assessment of quality of life after 12 months of treatment | 12 months | Assessment of quality of life after 12 months of treatment |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01315795
GET https://conductscience.org/api/trials/v1/NCT01315795/registered